IV 

118TH CONGRESS 

2D SESSION H. RES. 1285 

Condemning the pro-abortion policies of the Biden administration. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 7, 2024 

Mr. MORAN (for himself, Mr. SMITH of New Jersey, Mr. BIGGS, Mr. BANKS, 

Mr. DUNCAN, Mr. BABIN, Mr. GUEST, Mr. PALMER, Mr. FLEISCHMANN, 

Mr. MOONEY, Mrs. BICE, Mrs. MILLER of Illinois, Mr. GOSAR, Mr. 

WEBER of Texas, Ms. BOEBERT, Mr. PFLUGER, Mr. CRENSHAW, Mr. 

MOORE of Alabama, Mr. FULCHER, Mr. KUSTOFF, Mr. GOODEN of 

Texas, Mr. WEBSTER of Florida, Mr. MOOLENAAR, Mrs. LESKO, Mr. 

ADERHOLT, Mr. SESSIONS, Mr. AUSTIN SCOTT of Georgia, Mr. BILIRAKIS, Mrs. HARSHBARGER, Mr. CARTER of Texas, Mr. BURGESS, Mr. 

PENCE, Mr. HIGGINS of Louisiana, Mr. CLINE, Mr. CRANE, Mr. OGLES, 

Mr. SELF, Mr. HERN, Mr. DUNN of Florida, and Ms. FOXX) submitted 

the following resolution; which was referred to the Committee on Energy 

and Commerce 

RESOLUTION 

Condemning the pro-abortion policies of the Biden 

administration. 

Whereas in this resolution, the term ‘‘induced abortion’’— 

(1) means a procedure with the intent to deliberately 

end the life of the unborn child in their mother’s womb; 

and 

(2) excludes procedures for the management of 

intrauterine fetal death, spontaneous miscarriage, ectopic 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HRES 1285 IH 

pregnancy, fetal remains, and that are necessary to preserve the life of a pregnant woman or girl; 

Whereas chemically induced abortion in the United States 

most commonly occurs through a two-drug process where 

the mother— 

(1) first takes mifepristone, a drug that blocks progesterone, a hormone that is necessary for a baby developing in the womb; and 

(2) later takes misoprostol, a drug that causes the 

uterus to contract, evacuating the baby and the other 

contents; 

Whereas when the Commissioner of Food and Drugs initially 

approved mifepristone in 2000, they exceeded their statutory authority, claimed pregnancy was a life-threatening 

illness in order to fast-track approval of the drug and 

jeopardized the health and safety of women and girls; 

Whereas the Commissioner of Food and Drugs failed to 

study the effects of the drug on minors, as required by 

Federal law, and failed to study the safety of the drug 

under the labeled conditions of use; 

Whereas mifepristone can cause complications, including lifethreatening hemorrhaging, infection, incomplete induced 

abortions that require the need for emergency surgery, 

and mental health issues; 

Whereas, according to the Food and Drug Administration’s 

own label for mifepristone, roughly one in twenty-five 

women will end up in the emergency room after taking 

these drugs; 

Whereas the Commissioner of Food and Drugs issued a risk 

evaluation and mitigation strategy (in this preamble referred to as a ‘‘REMS’’) under section 505–1 of the FedVerDate Sep 11 2014 01:50 Jun 08, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6300 E:\BILLS\HR1285.IH HR1285

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HRES 1285 IH 

eral Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) to 

attempt to mitigate the risks mifepristone poses to the 

health of women and girls; 

Whereas the initial safety requirements issued by the Commissioner of Food and Drugs when administering 

mifepristone— 

(1) limited the indicated use of the drug to seven 

weeks gestation; 

(2) required at least three in-person doctor visits; 

(3) ensured in-person dispensing; and 

(4) required providers to report the occurrence of 

adverse events; 

Whereas adverse events are defined in section 604–3 of the 

Federal Food, Drug, and Cosmetic Act (21 U.S.C. 364) 

as any health-related event associated with the use of a 

cosmetic product that is adverse; 

Whereas in 2016, the Commissioner of Food and Drugs 

issued an updated REMS for mifepristone that abandoned many of the initial safety requirements; 

Whereas the Commissioner of Food and Drugs also removed 

the requirement for prescribers to report non-lethal adverse events resulting in incomplete data collection to 

monitor complications from mifepristone; 

Whereas in the 2016 updated REMS, the Commissioner of 

Food and Drugs— 

(1) increased the gestation period where 

mifepristone may be taken from 7 weeks to 10 weeks; 

(2) permitted non-physicians, who have less training 

in handling complications from mifepristone, to prescribe 

mifepristone; and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HRES 1285 IH 

(3) decreased mandatory office visits for patients 

from three to one, including eliminating the in-person follow-up examination that ensures a woman or girl has not 

suffered complications or retained fetal remains; 

Whereas the Commissioner of Food and Drugs eliminated 

prior requirements that prescribers report all serious 

complications from mifepristone; 

Whereas the Commissioner of Food and Drugs does not have 

access to national data for chemically induced abortions 

or for complications from abortions; 

Whereas the decision of the Commissioner of Food and 

Drugs to no longer require prescribers to report adverse 

events, other than death, further weakened the accurate 

data the Food and Drug Administration has access to; 

Whereas one study estimates that the Food and Drug Administration may be missing data on up to 95 percent of serious adverse events; 

Whereas serious adverse events are defined in section 604– 

5 of the Federal Food, Drug, and Cosmetic Act (21 

U.S.C. 364) as any adverse event that results in death, 

a life-threatening experience, inpatient hospitalization, a 

persistent or significant disability or incapacity, a congenital anomaly or birth defect, an infection, or significant disfigurement (including serious and persistent rashes, second- or third-degree burns, significant hair loss, or 

persistent or significant alteration of appearance), other 

than as intended, under conditions of use that are customary or usual or requires, based on reasonable medical 

judgment, a medical or surgical intervention to prevent 

such outcomes; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HRES 1285 IH 

Whereas in 2021, based on incomplete and unreliable data, 

the Commissioner of Food and Drugs eliminated the last 

remaining in-person office visit that ensured women and 

girls do not have ectopic pregnancies or other life-threatening conditions before taking mifepristone; 

Whereas the abandonment of these safeguards by the Commissioner of Food and Drugs has allowed for chemically 

induced abortions by mail and online; 

Whereas women and girls can now receive mifepristone without ever seeing a practitioner and without any certainty 

that follow-up care is available for potentially life-threatening complications; 

Whereas women and girls located far from medical care centers will suffer disproportionately because they may need 

to quickly access a hospital to receive emergency surgery, 

blood transfusion, or intravenous antibiotics, but are unable to access this care quickly; 

Whereas in 2023, the Commissioner of Food and Drugs approved an updated REMS for mifepristone that— 

(1) permanently removed the requirement that 

health care providers personally dispense mifepristone; 

and 

(2) allowed certified pharmacies from both physical 

locations and online retailers to dispense mifepristone; 

Whereas there are no age limits on prescribing mifepristone, 

nor do the REMS for mifepristone require parental consent or notice, meaning these drugs can be sent through 

the mail to minors without the knowledge or consent of 

their parents; 

Whereas removing the in-person dispensing requirement has 

intensified health risks for women and girls by removing 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HRES 1285 IH 

the ability of practitioners to diagnose an ectopic pregnancy through an ultrasound, which is the key method of 

diagnosis; 

Whereas mifepristone has no effect on an embryo implanted 

outside the uterus, which could cause a woman or girl 

with an undiagnosed ectopic pregnancy, who has taken 

mifepristone, to believe she is no longer pregnant because 

the early symptoms of a ruptured ectopic pregnancy, 

such as heavy bleeding, mirror those of a chemically induced abortion; 

Whereas in reality the woman or girl would be at risk of rupturing a fallopian tube, or another organ, leading to catastrophic hemorrhaging and maternal death; 

Whereas ectopic pregnancies occur in 1 out of every 50 pregnancies; 

Whereas removing the in-person dispensing requirement prevents providers from determining the gestational age of 

a baby; 

Whereas more than one out of every three women or girls 

who take mifepristone during their second trimester will 

require surgery; 

Whereas removing the in-person dispensing requirement prevents providers from administering RhoGAM to women 

or girls with Rh negative blood to prevent potentially 

fatal complications for a baby in a future pregnancy; 

Whereas removing the in-person dispensing requirement prevents providers from screening for coercion, which can 

cause providers to be uncertain about whether the 

mifepristone is being taken by the woman or girl to 

whom it is being dispensed to and whether it is being 

taken willingly; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•HRES 1285 IH 

Whereas mifepristone has been used by domestic abusers to 

unknowingly drug pregnant women and girls and to kill 

unborn babies; 

Whereas mifepristone is also used by sex traffickers to coerce 

their victims into having an induced abortion without seeing a health care provider, which can be a key opportunity for the victims of sex trafficking to be identified 

and assisted: and 

Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) condemns the Commissioner of Food and 

3 Drugs for lessening patient safeguards around a 

4 dangerous drug; 

5 (2) finds that the announcement from the 

6 Biden administration, on January 3, 2023, that 

7 health care providers are no longer required to per8 sonally dispense mifepristone, endangers the health 

9 of women and girls and enables reproductive coer10 cion by human traffickers and domestic abusers; and 

11 (3) condemns the Biden administration for its 

12 pro-abortion policies that prioritize abortion busi13 nesses over the health and safety of women and 

14 girls. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB